Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Gojek-Tokopedia Merger: A Blockbuster Deal and Potentially Better than a Gojek-Grab Ride

New Horizon Health IPO: Aiming to Become Pioneer in Cancer Screening

Genor Biopharma IPO: Strong Clinical Pipeline with Some Potential Blockbusters

Yidu Tech IPO Valuation: Attractive at the Low-End but Superior Growth Profile Justifies the Premium

Hygeia Healthcare IPO (Part II): Healthy Valuation

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Kuaishou IPO: Stable Profits Seem Possible with Cost Discipline and Expanding Revenues

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Gracell Biotechnologies Inc / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/gracell-biotechnologies-inc" target="_blank" data-smartkarma-citation="entities:31108:1" rel="noopener">Gracell Biotechnologies Inc (GRCL US)</a>  is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfil unmet medical needs in the treatment of cancer.The company has filed for an IPO to list its shares in the US and plans to raise around US$150m at the midpoint of the IPO price range of US$16-18 per ADS.The company has built two proprietary technology platforms FasTCAR and TruUCAR that disrupts conventional CAR-T cell therapies. Gracell’s lead FasTCAR autologous candidate, GC012F, is being developed for the treatment of patients with multiple myeloma and is being studied in Phase 1 trial in China.The company has two GMP-compliant manufacturing facilities in China that enable to be self-sufficient in the production of CAR-T cells for clinical development and early-stage commercialization.Gracell Biotechnologies currently does not have any products approved for commercial sale; hence the company does not generate any revenues from product sales. However, the company’s drug development pipeline includes a few strong candidates that shows good potential.

Gracell Biotechnologies Inc (GRCL US)  is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfil unmet medical needs in the treatment of cancer.The company has filed for an IPO to list its shares in the US and plans to raise around US$150m at the midpoint of the IPO price range of US$16-18 per ADS.The company has built two proprietary technology platforms FasTCAR and TruUCAR that disrupts conventional CAR-T cell therapies. Gracell’s lead FasTCAR autologous candidate, GC012F, is being developed for the treatment of patients with multiple myeloma and is being studied in Phase 1 trial in China.The company has two GMP-compliant manufacturing facilities in China that enable to be self-sufficient in the production of CAR-T cells for clinical development and early-stage commercialization.Gracell Biotechnologies currently does not have any products approved for commercial sale; hence the company does not generate any revenues from product sales. However, the company’s drug development pipeline includes a few strong candidates that shows good potential.

Gracell Biotechnologies IPO: Promising Early Trial Results but Nowhere Close to Commercialisation